<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In December 1997, we conducted a nationwide survey of cases of primary allogeneic peripheral blood stem cell transplantation (allo-PBSCT) performed in Japan between December 1994 and November 1997 Data was collected on 103 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, or <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Eighty-seven patients received transplants from HLA-identical siblings, and 16 from HLA-mismatched related donors </plain></SENT>
<SENT sid="2" pm="."><plain>Granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSC) were collected from donors by 1 to 3 aphereses </plain></SENT>
<SENT sid="3" pm="."><plain>Apheresis products contained a median 5.4 (1.0-30.4) x 10(6) CD34 + cells/kg </plain></SENT>
<SENT sid="4" pm="."><plain>Most patients were given <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prophylaxis </plain></SENT>
<SENT sid="5" pm="."><plain>Median days to ANC &gt; 500/microliter and platelets &gt; 50,000/microliter were 13 (7-49) and 16 (10-94), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD developed in 37/99 (37.4%) and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD in 59/86 (68.6%) patients </plain></SENT>
<SENT sid="7" pm="."><plain>The incidence of treatment-related mortality within 100 days after transplant was 16.1% </plain></SENT>
<SENT sid="8" pm="."><plain>Fifty-five patients (59.6%) were alive after a median follow-up of 794 days </plain></SENT>
<SENT sid="9" pm="."><plain>More patients and longer follow-up periods will be required to assess the efficacy of allo-PBSCT and evaluate graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> effect along with the incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
</text></document>